Armoring multifunctional T cells for cancer therapy

Informations projet

ARMOR-T

N° de convention de subvention: 756017

DOI

10.3030/756017

Projet clôturé

Date de signature de la CE 20 Septembre 2017

Date de début 1 Mars 2018

Date de fin 29 Février 2024

Financé au titre de

• EXCELLENT SCIENCE - European Research Council (ERC)

Coût total

€ 1 636 710,00

Contribution de l’UE

€ 1 636 710,00

Coordonné par

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 4 - ARMOR-T (Armoring multifunctional T cells for cancer therapy)

Période du rapport: 2022-09-01 au 2024-02-29

Résumé du contexte et des objectifs généraux du projet

Cellular therapies are the therapeutic use of T cells which have become part of the standard of care in certain blood-borne cancers indications, related to a minority of cancer patients.. From basic studies, it is expected that this type of treatment should be applicable to much more frequent situations and diseases such as solid cancer types. In contrast, clinical studies so far failed to demonstrate activity in these diseases. A major reasons lays in a very different biology between solid and hematological cancers. These key differences have so far been overlooked in cell therapy development. ARMOR-T has taken up the challenge to solve these problems by means of engineering of cells. Such novel therapeutic pipeline has the potential to offer promising treatments to patients suffering from a wide variety of cancer types such as pancreatic, colon or breast cancer. ARMOR-T has a) established novel methods of engineering, b) selected promising engineering combinations and c) tested and characterized such novel strategies. ARMOR-T has layed the basis for further preclinical development and future clinical testing.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

ARMOR-T has set out to validate novel tumor targeting platforms utilizing specific immune cells, so called T cells (such as Karches et al., Clin Can Res 2019 and Stock, JITC 2022). ARMOR-T could also establish a novel technique of genetic modification of T cells to ameliorate tumor tissue recruitment and prove its efficacy in preclinical models (Lesch et al., Nat Biomed Eng 2021 and Cadilha et al., Science Adv. 2021). ARMOR-T has also pioneered a method for identifying novel tumor-associated target structures and design novel receptors against these (such as Gottschlich et al., Nat Biotech 2023 and Märkl et al., Nat Com 2024). These results have been broadly presented at scientific meetings (such as ESMO and ESMO IO) and the most promising candidates are now in further preclinical development towards therapy.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Previous work has mainly focused on effectively targeting the cancer cell and has already led to the approval of gene engineered T cells for distinct indications. The particular biology of non-hematological cancer types has however been mostly disregarded. ARMOR-T has proposed to specifically address said differences through multiple engineering. Such approach has the potential to offer a unique therapeutic avenue for patients suffering from multiple cancer types. ARMOR-T has pioneered novel approaches involving cell engineering and will now progress to developping actual products for future clinical testing and application.

Lytic synapse formation between two T cells and one tumor cell